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Abstract
Background and aims: Few studies have explored how polygenic propensity to cannabis use 
unfolds across development, and no studies have yet examined this question in the context of 
environmental contributions such as peer cannabis use. Outlining the factors that contribute to 
progression from cannabis initiation to problem use over time may ultimately provide insights into 
mechanisms for targeted interventions. We sought to examine the relationships between polygenic 
liability for cannabis use, cannabis use trajectories across ages 12–30, and perceived peer cannabis 
use at ages 12–17.
Corresponding author: Emma C Johnson, emma.c.johnson@wustl.edu, 314-273-1873, Department of Psychiatry, Washington 
University School of Medicine, 660 S. Euclid, CB 8134, St. Louis, MO 63110. 
The authors declare no conflicts of interest.
HHS Public Access
Author manuscript
Addiction. Author manuscript; available in PMC 2020 April 01.
Published in final edited form as:
Addiction. 2019 April ; 114(4): 687–697. doi:10.1111/add.14512.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Design: Mixed effect logistic and linear regressions were used to examine associations between 
polygenic risk scores, cannabis use trajectory membership, and perceived peer cannabis use.
Setting: USA
Participants: From the Collaborative Study on the Genetics of Alcoholism (COGA) study, a 
cohort of 1,167 individuals aged 12–26 years at their baseline (i.e., first) interview.
Measurements: Key measurements included lifetime cannabis use (yes/no), frequency of past 
12-month cannabis use, maximum lifetime frequency of cannabis use, cannabis use disorder 
(using DSM-5 criteria), and perceived peer cannabis use. Polygenic risk scores (PRS) were created 
using summary statistics from a large (N = 162,082) genome-wide association study (GWAS) of 
cannabis use.
Findings: Three trajectories reflecting no/low (n=844), moderate (n=137) and high (n=186) use 
were identified. PRS were significantly associated with trajectory membership (p=0.002 – 0.006, 
maximum conditional R2 = 0.014, ORs = 1.40 – 1.49). Individuals who reported that most/all of 
their best friends used cannabis had significantly higher PRS than those who reported that none of 
their friends were users (OR = 1.35, 95% C.I. = [1.04, 1.75], p = 0.023). Perceived peer use itself 
explained up to 11.3% of the variance in trajectory class membership (OR: 1.50 – 4.65). When 
peer cannabis use and the cannabis use PRS were entered into the model simultaneously, both the 
PRS and peer use continued to be significantly associated with class membership (p < 0.01).
Conclusions: Genetic propensity to cannabis use derived from heterogeneous samples appears 
to correlate with longitudinal increases in cannabis use frequency in young adults.
Introduction
The growing controversy regarding cannabis legalization in the United States1 is based in 
part on the question of whether increased access is associated with escalations of both use 
and misuse2, with the latter currently affecting about 6% of the population3. Longitudinal 
studies have classified young cannabis users into those who remain casual users, those who 
transition to moderate levels of use and remain stable, those who show initial increases 
followed by declines in use and, importantly, those who demonstrate accelerated use and 
progression to problem use4–11. Outlining the factors that contribute to the likelihood of 
progression to problem use might provide insights into targets for intervention.
Cannabis use and misuse are heritable (h2=50–70% of the variation). Several genomewide 
association studies (GWAS) have attempted to identify loci that might contribute to this 
heritable variation12–18. For cannabis use, the largest published study to date (N = 184,765 
individuals of European descent19; results used here on n=162,082; see Supplemental 
Materials for details) identified four independent genomewide significant loci and found a 
genomewide single nucleotide polymorphism (SNP) heritability of 10%, suggesting that the 
aggregated effects of common SNPs captured a sizeable portion of the heritability of 
cannabis use. Polygenic risk scores (PRS) offer a complementary approach to the study of 
such aggregated effects20. In brief, a PRS is a person-specific index of genetic propensity to 
a trait (e.g., cannabis use); PRS are constructed by multiplying the effect size from a 
discovery GWAS by the number of risk alleles that an individual possesses at that SNP. PRS 
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approaches are widely used in psychiatric genetics, including substance use and dependence, 
and can be used to assess whether genetic risk for one disorder or trait is associated with 
aspects of the same trait, or with a correlated disorder/trait21,22. For instance, one study 
found that PRS for schizophrenia risk predicted cannabis use in individuals with bipolar 
disorder23. However, few studies have explored how genetic propensity to cannabis initiation 
(i.e., cannabis PRS) influences patterns of cannabis use across development.
In addition to genetic risk, affiliations with cannabis-using peers are believed to be amongst 
the leading contributors to persistent cannabis use8,11,24,25. However, results from 
longitudinal samples remain mixed (e.g.,7). While peer use is readily viewed as an 
“environmental” agent of risk, it can also represent heritable aspects of underlying behavior, 
with at least one study suggesting a heritability of 25–28% for general peer group deviance, 
a broad measure including peer marijuana use26. That study also found that about 50–78% 
of the genetic variance in peer group deviance was attributable to genetic factors related to 
cannabis use27–29. Another study30 reported that the heritability of perceived peer alcohol 
use ranged from 7% at age 12–14 up to 38% by age 18, and that the relationship between 
peer alcohol use and one’s own alcohol use was attributable to genetic factors with a 
correlation of 0.83. Taken together, these observations raise the possibility that polygenic 
risk for cannabis use may interface with peer cannabis use in several possible ways, ranging 
from a main effect to a potential interactive effect. To our knowledge, these hypotheses 
remain untested.
To better understand the role of genetic propensity and peer use in the longitudinal course of 
cannabis use, we used data on 1,167 individuals of European descent who were part of a 
large longitudinal study of the genetics of addictions. We first identified trajectories of 
cannabis use frequency, and then examined whether trajectory class membership was related 
to (a) cannabis use PRS and/or (b) perceived peer cannabis use when the subject was 12–17 
years old. We also examined whether the relationship between polygenic risk, perceived peer 
use and trajectory membership could be explained by an interaction model where perceived 
peer use moderated the influence of polygenic risk on trajectory membership. Results from 
these analyses can provide a framework for how genetic liability and peer use might 
interface to shape the developmental unfolding of cannabis use.
Methods
Participants
The Collaborative Study on the Genetics of Alcoholism (COGA) study recruited alcohol 
dependent probands through substance use treatment programs at 7 sites across the United 
States. Probands and their family members were invited to participate, resulting in an 
overrepresentation of densely affected multiplex pedigrees. Control families (2 parents and 3 
or more offspring over the age of 14) were also selected from a variety of community 
sources (e.g., driver license registries). The institutional review boards for all 7 data 
collection sites, and additional data analysis sites, approved the study31.
For the current analyses, data from a cohort of 3,618 individuals (“September 2017” data 
freeze), who were aged 12–26 years at their baseline (i.e., first) interview, and comprised the 
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longitudinal component of COGA, were used32. Briefly, participants were offspring of 
COGA families, with 61.6% having one parent with alcohol use disorder. Since 2004, 
participants have been interviewed every 2 years with the same structured interview; follow-
up interviews are ongoing. We included only subjects with GWAS data and of European-
American (EA; as verified by genotype) descent to match the ethnicity of the discovery 
GWAS13 (n=1,897); of these individuals, 1,840 had non-missing data for relevant variables. 
For the longitudinal growth curve analyses, a further reduction in sample size resulted from 
sub-setting on those who were EA, had GWAS data, and had 3 or more assessments, 
including the baseline assessment (final analytic n = 1,167). When compared to the larger 
subset of 1,840 individuals, those with 3 or more assessments did not vary of any 
demographic or cannabis-related characteristics, suggesting that selection for those with ≥3 
assessments did not significantly bias findings (Table S1).
Assessment: All individuals were interviewed using a version of the Semi-Structured 
Assessment for the Genetics of Alcoholism (SSAGA33,34) with individuals aged <18 years 
administered a child version (C-SSAGA33,34).
Lifetime cannabis use was coded using all assessment responses to an item on whether they 
had ever used cannabis (response: yes or no).
Frequency of past 12 month cannabis use was also recorded as the response at each 
interview to an item querying how often the participant had used cannabis in the past 12 
months; the range was from 0 to 935. Data were winsorized to remove outliers (>3 standard 
deviations) at each age and were binned into 31 categories in 20-unit intervals. The interval 
length was chosen to capture variation in the data and allow for model optimization 
(sensitivity analyses with a 10-unit interval were also conducted; see Supplemental 
Materials).
Maximum lifetime frequency of cannabis use was the maximum reported frequency of past 
12 month cannabis use; this variable was log-transformed before analysis due to being right-
skewed.
Cannabis Use Disorder (CUD) was coded using DSM-5 criteria35 (without the requirement 
for clustering of symptoms).
Perceived peer cannabis use was coded as the response to an item: When you were 12–17, 
how many of your best friends used marijuana? (0 = none, 1 = a few, 2 = most, 3 = all; 
categories representing “most” and “all” were combined as the latter was only endorsed by 
35 individuals); To minimize recall bias, peer use reported at the last assessment was used 
for those aged 12–17 (n=818), and at the assessment closest to age 12–17 for subjects aged 
18 and older (349, although 91% were 18–21 years of age).
Genotypic data:
Members of COGA’s prospective cohort were genotyped as a part of multiple initiatives on 
different Illumina and Affymetrix arrays. The reported pedigree structure was assessed using 
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a pruned set of 1,519,440 SNPs. In total, 6,881,872 SNPs passed quality control and data 
cleaning thresholds and were available for analysis (details in Supplemental Materials).
Polygenic risk for cannabis use: Effect sizes and effect alleles were derived from 
genome-wide summary statistics from a large GWAS meta-analysis of 162,082 individuals, 
all of European ancestry (characteristics of discovery GWAS19 in Supplemental Materials). 
PRS were created for each COGA individual of genetically verified European descent with 
SNPs meeting increasingly lenient p-value thresholds from the discovery GWAS (from pT 
<0.0001 to pT <0.50). Details are provided in Supplementary Materials but briefly, for each 
COGA individual, effect sizes from the discovery GWAS by Pasman et al., were multiplied 
by the number of effect alleles for each SNP, and then averaged across all SNPs within a 
certain p-value threshold (e.g,. pT <0.10) (e.g., tuning parameter36) in the discovery GWAS 
to create one score per individual for that pT. This pT threshold is not reflective of 
significance of the PRS in a traditional statistical sense (i.e., p < 0.05). Instead, it is 
predicated on the assumption of a high degree of polygenicity, which has been found to be 
true for most complex traits37; therefore, SNPs that do not reach stringent genome-wide 
significance cutoffs (typically p < 5e-8) in the discovery GWAS are still predicted to make 
small but incremental and additive contributions to risk liability for the outcome20,38,39.
Covariates: Sex, age at first (i.e., baseline) and last interview were included as covariates. 
Two additional covariates were also included. First, three principal components, reflecting 
continuous variation in genetic ancestry were derived from all the GWAS data (details in 
Supplemental Materials) and included to account for subtle ancestral differences40. Second, 
the type of genotyping array used for each individual was included as a covariate in order to 
control for potential differences in genomic content, quality control or imputation (Table S1 
for descriptive data).
Statistical Analyses
Estimation of Trajectories: Only subjects with GWAS data and cannabis frequency of 
use data available at 3 or more assessment waves (N=1,167) were included in the growth 
mixture models. Latent class growth analysis (LCGA) with a zero-inflated Poisson model in 
MPlus v841 was used to assign these individuals to classes that were derived using cannabis 
past year frequency of use categories from each of the up to 7 interviews (baseline through 
12 - year follow-up). Age at assessment was used as the analytic unit (i.e., the x-axis). 
Analysis details are available in Supplemental Materials.
PRS analyses: The PRS were standardized (using the ‘scale’ function in R) before 
analysis. Mixed effect logistic regression models were used to test the association between 
PRS (at varying pT) and trajectory class membership (using pairwise comparisons between 
classes), the associations between peer use and trajectory class membership,between the 
PRS and peer use and also to test whether an interaction between PRS and peer cannabis use 
predicted trajectory membership, while accounting for all second order interaction terms 
(see42). All analyses included the family identifier and recruitment site as random effects 
(family nested within site).
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All of the above analyses were conducted in R43. To assess model fit and the relative amount 
of variance explained by the PRS, we used the ‘MuMIn’ package in R to calculate both 
marginal and conditional R2 for each mixed model43. We use the conditional R2 to select the 
most predictive pT (see Supplemental Materials), but report both statistics for the most 
predictive PRS threshold. The proportion of variance attributable to the PRS (Δconditional 
R2) was estimated as the difference between the conditional R2 for a model with covariates 
alone and the model that included covariates and the PRS (i.e. conditional R2(full model) - 
conditional R2(model without PRS)). The use of ΔR2 (typically Nagelkerke’s pseudo-R2 for 
binary traits20) as an index of the most predictive PRS relates to its role as an index of 
predictor efficacy38,39,44, such that the addition of the PRS to a model improves the fit of the 
model, thus indicating unique variance attributable to the PRS, over and above covariates. 
As peer use was restricted to recall at age 12–17, we did not test whether trajectory 
membership influenced future peer use. The Bonferroni-corrected significance threshold for 
the PRS analyses was set at 0.0019 (corrected for 27 tests: 3 class comparisons x 9 PRS 
thresholds), while the significance threshold was set at α < 0.05 for the remaining analyses. 
In addition, to overcome concerns that uncertainty in class membership might have 
influenced results, we reran analyses for the most predictive PRS threshold using the BCH 
approach in MPlus45. In this approach, the LCGA model is fitted to data and weights are 
assigned to likelihood of membership in each class while simultaneously examining 
between-class differences in PRS and accounting for the effect of covariates on class 
membership (see Supplemental Materials).
Role of externalizing behaviors: To examine whether cannabis use PRS represented a 
general propensity to externalizing behaviors, we examined their association with (a) the 
thrill/adventure-seeking and the disinhibition subscales from Zuckerman’s sensation-scale 
(from baseline assessments; for adults46; Russo’s modified sensation-seeking scale for 
children47; standardized) and (b) with a lifetime diagnosis of conduct disorder from the 
SSAGA.
Negative control analyses: As a negative control, we also tested whether the PRS 
significantly predicted height at baseline, a trait not expected to be genetically associated 
with cannabis use.
Results
Trajectories of recent cannabis use
As shown in Figure S1, three classes were identified as the three-class model had a lower 
Bayesian Information Criterion (BIC) than the two-class solution, the Lo-Mendel-Rubin 
Adjusted Likelihood Ratio Test (LMR-ALRT) p-value for the 4 class solution (p = 0.1002) 
was not significant, and the entropy for the 3 class solution (0.917) was high (fit statistics in 
Table S2; parameter estimates for the best-fitting model in Table S3). Classification 
probabilities were high (0.975, 0.928, 0.977). Sensitivity analyses with 10-unit intervals of 
cannabis use frequency were similar (Table S2; Supplemental Materials). Broadly 
speaking (Table 1), the classes represented (a) users who consistently used cannabis 
infrequently during the entire period of follow-up, and included never users of cannabis, that 
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we termed the “no-low” use class (N = 844); (b) another class that included individuals with 
very high frequency of initial use that continued to escalate during the follow-up period and 
remained elevated at the final assessment, that we termed the “high” use class (n=186); and 
(c) a class that included escalating use that involved similar high use at baseline but a less 
steep increase in use during the follow-up, that we termed the “moderate” use class (N = 
137). Also, as shown in Table 1, those in the high and the moderate use trajectories were 
significantly more likely to be male, have used cannabis at an earlier age, and meet criteria 
for a lifetime history of cannabis use disorder (CUD) as well as conduct disorder.
Associations between cannabis use PRS and overall cannabis use in the sample
In the analytic sample (n=1,167), we found no evidence that the cannabis PRS was 
associated with a binary measure of lifetime cannabis use (p = 0.111), nor with frequency of 
use at baseline (in ever-users, p = 0.390), frequency of use at last assessment (in ever-users, 
p = 0.513), or maximum frequency of cannabis use (in ever-users, p = 0.090). However, the 
cannabis use PRS was associated with lifetime history of DSM5 CUD (p = 0.028) but was 
no longer significant in the subset of ever-users (p = 0.090, Table S4). The pattern of 
association with cannabis use was similar when individuals with <3 assessments (n=1,840) 
were studied, although in this larger sample the PRS was associated with maximum 
frequency of cannabis use (p = 0.013), and with DSM5 cannabis use disorder in both the full 
sample (p = 0.005) including in ever-users (n = 1,144, p = 0.014).
Cannabis use PRS predicting cannabis use trajectories
The cannabis use PRS was significantly associated with cannabis use trajectory class 
membership (Table 2). At the most significantly-associated PRS threshold of pT < 0.1, the 
cannabis use PRS explained approximately 1.4% of the conditional variance in high vs. no-
low class membership (2.30% of the marginal variance); for every unit increase in PRS, 
membership in the high vs. no-low class increased by an odds of 1.40 (95% CI = [1.13, 
1.74]) (Figure S2; full results for all thresholds in Table 2, all covariates in Table 3). 
Cannabis PRS also explained 3.6% of the conditional variance in high vs. moderate class 
membership, although this comparison did not survive Bonferroni correction (OR = 1.49, 
95% CI = [1.12, 1.97], p = 0.006). There was no evidence that cannabis use PRS was 
associated with height at baseline (p = 0.730). Results from the BCH approach identified 
identically significant differences in mean PRS across the high class when compared with 
the moderate and the no-low class (Table S5).
Peer cannabis use predicting cannabis use trajectories
Of the 1,162 individuals with peer use data available, 57.5, 28.3 and 14.2% reported that 
none, few and most-all of their close peers used cannabis. Perceived peer cannabis use 
explained up to 11.3% of the variance in trajectory class membership (ORs = 1.50 – 4.65). 
When peer cannabis use and the cannabis use PRS were entered into the model 
simultaneously, the association between the cannabis use PRS and membership in high vs. 
moderate class was only slightly attenuated (OR: 1.46 [95% C.I. = [1.09, 1.94]; p = 0.010), 
as was the association with the high vs. no-low class comparison (OR: 1.34 [95% C.I. = 
[1.07, 1.68]; p = 0.012). Peer cannabis use was independently and significantly associated 
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with all three comparisons in these models that also included the PRS as a predictor (both 
high vs. no-low and moderate vs. no-low p < 0.001, high vs. moderate p = 0.017).
Cannabis use PRS predicting peer cannabis use
Those who reported that most-all of their best friends used cannabis had significantly higher 
PRS than those who reported that “none” of their best friends used cannabis (most 
significant OR = 1.38, 95% C.I. = [1.07, 1.78], p = 0.012). Other comparisons (e.g., none vs. 
few: p = 0.799; few vs. most-all, p = 0.096) did not significantly differ from each other on 
cannabis PRS (details in Supplemental Material).
Role of externalizing behaviors:
The disinhibition scale score was significantly associated with both trajectory membership 
and all peer cannabis use comparisons, while thrill-seeking was only significantly associated 
with belonging to the high trajectory class vs.no-low class and with the peer cannabis use 
comparison between none vs. a few (details in Table S6). Cannabis use PRS did not 
significantly predict either scale, but was significantly associated with conduct disorder 
diagnosis, as were peer use and all three of the trajectory class comparisons (Table S6). The 
association between peer use and trajectory membership (high vs. no-low class: p < 0.001; 
high vs. moderate: p = 0.037; moderate vs. no-low: p = < 0.001) was only somewhat 
attenuated when including conduct disorder as a covariate. Inclusion of conduct disorder 
also modestly attenuated the association between PRS and class membership (e.g., high vs. 
no-low class: ORconduct = 1.37, 95% CI = [1.11, 1.69], p = 0.003; vs ORno-conduct: 1.40, 95% 
CI = [1.13, 1.74], p = 0.002; high vs. moderate ORconduct = 1.45, 95% CI = [1.10, 1.90], p = 
0.008 vs. ORno-conduct= 1.49, 95% CI = [1.12, 1.97], p = 0.006).
PRS x peer use predicting cannabis use trajectories
PRS-by-peer use interaction was not significant (Table S7), suggesting independent effects 
of PRS and peer use on trajectory membership.
Discussion
There are three key implications from our study. First, we found a statistically significant 
association between cannabis PRS and trajectory membership, and the effect size (Δ 
conditional R2 up to 3.6%) was consistent with other PRS analyses21. Thus, genetic 
propensity to cannabis initiation derived from a large, heterogeneous discovery sample 
appears to differentiate between classes derived from frequency of cannabis use in an 
ascertained, longitudinal cohort. Interestingly, lifetime cannabis use was not significantly 
related to PRS. However, maximum frequency of use and DSM5 CUD were associated with 
PRS in the larger sample of 1,840. It is possible that even though the discovery GWAS was 
aimed at assessing genetic propensity to lifetime use, that polygenic liability is better 
captured along a developmental spectrum in these data. While, to some extent, the classes 
differed in severity of use (e.g., CUD), associations with class membership (e.g., high vs. 
no-low) far exceeded cross-sectional associations with CUD, suggesting that class 
membership in this young and ascertained sample may be a superior index of genetic 
propensity than cross-sectional indices alone.
Johnson et al. Page 8
Addiction. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Second, the “environmental” risk factor in our study, perceived peer cannabis use explained 
up to 11.3% of the variance in trajectory membership. This suggests that, although genetics 
certainly plays a role in the progression of cannabis use, established environmental 
influences such as peer use are better predictors of cannabis use than PRS at the moment, 
and this is likely to be true for other complex behavioral traits as well. Uniquely, genetic 
propensity to cannabis use was also associated with greater perceived peer engagement in 
cannabis use. Consistent with prior heritability studies, this finding of genetic contributions 
to perceived peer use might reflect gene-environment correlation48,49 or causal processes, 
such as Mendelian randomization50. However, both PRS and peer use remained significantly 
associated with class membership when simultaneously modeled suggesting some 
independent effects.
Third, we found no evidence that peer cannabis use is a moderator of polygenic 
contributions to cannabis use trajectories. Previous studies have found some evidence for 
interaction effects between peer substance use and genetic liabilities for substance use48 but 
few have used genomewide PRS to do so.
Although results from the discovery GWAS for cannabis use were genetically correlated 
with risk-taking (SNP-rg =0.425, p=3.4e-42)19, we found no evidence that our measures of 
risk-taking were consistently related to the cannabis use PRS. Even though PRS were 
correlated with conduct disorder, associations between the PRS and trajectory membership 
persisted even after controlling for conduct disorder. Thus, general deviance does not appear 
to fully account for these associations.
Our study had several limitations, including a modest target sample size (target N = 1,167, 
discovery sample size N = 162,082; given the current sample size and a significance level of 
α = 0.05, our study had 80% power51 to detect an effect size of R2 ≥ 0.0068.). Further 
replication studies in larger, independent samples are warranted. Also, the current analyses 
were restricted to individuals of European ancestry, so we cannot confidently extrapolate our 
conclusions to other populations. Third, COGA is ascertained for genetic liability to 
addiction, which may have influenced findings. Our “high” group (16%) is somewhat larger 
than those noted in two prior general-population longitudinal studies6,8 but similar to one 
study that oversampled for tobacco4 smoking and lower than a study with overrepresentation 
of individuals from high-crime neighborhoods7. Thus, similar classes have been noted, 
although there is much variability in their class size. Fourth, while self-report of perceived 
peer use is commonly studied, and does not significantly differ from actual peer use52, it is 
possible that it is less objective than reports by peer nominees53. Furthermore, as we did not 
have reports of concurrent peer cannabis use at older ages (and the sample has a diverse age 
range at final assessment), we cannot speculate whether trajectory membership was 
associated with subsequent affiliations with cannabis-using peers. Fourth, we binned 
frequency of use data into 20-unit intervals and this may have obscured the identification of 
smaller classes. For instance, our method combined those using 1–2 times in the past year 
with those who may have used cannabis 15–20 times. However, sensitivity analyses with 10-
unit intervals provided similar results. It is also possible that reported frequency at the upper 
end of use was imprecise (e.g., using 550 vs. 600 times).
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It is hoped that with larger discovery efforts of both cannabis use54 and of cannabis use 
disorders, the predictive quality of PRS, not merely in terms of what they predict, but also 
when and how they do so, will be better elucidated. However, this study highlights that even 
as discovery GWAS sample sizes grow and PRS begin to attain a greater level of 
precision21,39, it will be of paramount importance to consider not only how genetic liability 
shapes health and behavior, but also the environmental context within which such behavior 
unfolds (e.g.,55).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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